David Marek, Myovant CEO

As FDA clears re­l­u­golix for uter­ine fi­broids, My­ovant, Pfiz­er gear up to take on Ab­b­Vie in com­mer­cial ri­val­ry

Pfiz­er and My­ovant have land­ed the key ap­proval need­ed to open up the women’s health side of their re­l­u­golix fran­chise, as the FDA clears a three-in-one pill to treat heavy men­stru­al bleed­ing as­so­ci­at­ed with uter­ine fi­broids.

Dubbed Myfem­bree, the drug — a com­bi­na­tion of re­l­u­golix, estra­di­ol and norethin­drone ac­etate — is the sec­ond in My­ovant’s mar­ket­ed port­fo­lio af­ter Or­govyx, which com­pris­es on­ly re­l­u­golix, was ap­proved for prostate can­cer in De­cem­ber. Both ther­a­pies and a third, for en­dometrio­sis, were all part of a $4.2 bil­lion com­mer­cial al­liance with Pfiz­er — lend­ing sig­nif­i­cant mus­cle as My­ovant goes up against Ab­b­Vie in a heat­ed mar­ket­ing bat­tle.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.